...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Classifying/taxonomy mCRPC patients

Toinv - You made the following statement.

"What we’ve seen from the zen3694 mCRPC trial is that zen3694 has very strong results in a few patients but not others."

I would say that the results might be stronger than you infer. Out of 24 of the Abiraterane progressors, 7 have passed Zenith's target with three still ongoing. Seven more are approximately at or passed SOC with three of them ongoing. Within the remaining 10, four are ongoing. That is 7 successful and 7 ongoing that might be successful so 14 out of 24 possibly successful.

Of the 37 progressed on Enzalutamide, six have passed Zenith's target (3 ongoing) with 5 more past SOC and ongoing. Of the other 26, twelve are ongoing. That is 6 successful and 17 more ongoing that might be successful so 23 out of 37 possibly successful. 

I don't think we want to let a few superstars taint our view of the rest as they might still be highly successful and who can guess how many more superstars might be lurking within them. 

Share
New Message
Please login to post a reply